Adial Pharmaceuticals, Inc. received a communication from the United States Securities and Exchange Commission (SEC) on January 19, 2024, regarding its Registration Statement on Form S-3, which was filed on January 12, 2024. The SEC informed the Chief Financial Officer, Joseph Truluck, that the agency has not reviewed and will not review the registration statement. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. Doris Stacey Gama was provided as a point of contact for any further questions.

Adial Pharmaceuticals, Inc. received a communication from the United States Securities and Exchange Commission (SEC) on January 19, 2024, regarding its Registration Statement on Form S-3, which was filed on January 12, 2024. The SEC informed the Chief Financial Officer, Joseph Truluck, that the agency has not reviewed and will not review the registration statement. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. Doris Stacey Gama was provided as a point of contact for any further questions.